A Phase II open-label single arm multicenter study of Avelumab with hypofractionated re-irradiation in adult subjects with transformed IDH mutant glioblastoma
Brief description of study
If you have been diagnosed with brain cancer classified as glioblastoma, with a mutation in the IDH1 or IDH2 genes, you may qualify to participate in a clinical trial. The main goal of this phase II trial is to evaluate the safety and determine how well you and your disease reacts to the investigational drug, Avelumab, an immunotherapy that targets PD-L1, and radiation. This study will also evaluate cancer cell growth (disease progression) is delayed in people taking Avelumab, also determine the relationship between biomarkers (proteins) of interest and the investigational drug Avelumab.
Clinical Study Identifier: s16-01179
ClinicalTrials.gov Identifier: NCTs16-01179
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
